Study of Antimicrobial Effects of Clarithromycin Loaded PLGA Nanoparticles against Clinical Strains of Helicobacter pylori

Abstract

Clarithromycin (CLR) formulation was prepared as PLGA nanoparticles in order to enhance the therapeutic effects using the distinctive features of a nanoparticulate delivery system. CLR loaded PLGA nanoparticles were prepared by Quasi Emulsion Solvent Diffusion (QESD) method using Poly lactic-co-Glycolic Acid (PLGA) as a biodegradable polymer. Antibacterial activity of the prepared formulations was evaluated against clinical strains of Helicobacter pylori, isolated from gastric biopsies of patients with gastritis, duodenal ulcer, peptic ulcer, and gastroesophageal reflux disease undergoing endoscopy, by using agar dilution method.Spherical nanoparticles with relatively narrow size distribution (between 200 and 800 nm) in the size range of 305 ± 138, 344 ± 148 and 362 ± 110 nm were achieved for F22, F23 and F23 respectively. CLR encapsulation percentages were measured to be 57.4 ± 4.3 to 80.2 ± 4.0%. CLR loaded PLGA nanoparticles showed equal or enhanced eradication effect against H. pylori strains according to the declined MIC values in comparison with the untreated CLR.In conclusion, the prepared CLR nanoformulation showed appropriate physicochemical properties and improved activity against H. pylori that could be a suitable candidate for oral preparations.

Nanomedicine Fight against Antibacterial Resistance: An Overview of the Recent Pharmaceutical Innovations

“…The enhanced antibacterial efficacy against H. pylori strains was evidenced from lower MIC values compared to free antibiotic. Although the mechanism remains unclear, it was postulated that PLGA-loaded nanoparticles could carry out either fusion or adsorption [128]. PCL can be utilized for producing good antimicrobial drug delivery nanosystems because of its biocompatibility and biodegradability [129].…”

Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies

“…PLGA (poly lactic- co- glycolic acid) are good candidates because due low toxicity and possibility to encapsulate low water-soluble drugs such as clarithromycin, in order to reach the target region [ 161 , 162 ]. PLGA nanoparticles loaded with clarithromycin, in size of about 360 nm, have shown MIC values in the range 0.003 µg/mL to 0.05 µg/mL, which were significantly lower than non-encapsulated drug solution, as demonstrated for clinical five H. pylori strains [ 162 ]. Gliadin, a biodegradable, biocompatible, and natural origin biopolymer, is known to adhere to mucosa membranes.…”

Aplicações Clínicas Dos Glicopeptídeos Nas Unidades De Terapia Intensivas

“…O princípio desta terapia se dá pelo carreamento dos antimicrobianos encapsulados por nanopartículas, que interagirem com o microrganismo promovendo uma lesão física na parede celular ou na membrana da bactéria, transportando por esta os antimicrobianos, ou adsorvendo a parede celular e liberando o antimicrobiano de forma contínua. Como resultado, é possível ver que há um aumento da ingestão de fármacos pelas bactérias com uma redução considerável dos efeitos tóxicos nos pacientes, quando comparados com a administração direta de antibióticos (KROLL FANG;ZHANG, 2017;LOTFIPOUR et al, 2016;SAFAROV et al, 2019).…”